CTNM — Contineum Therapeutics Share News
0.000.00%
Last trade - 00:00NASDAQ RESUMED AT 04:30 PM
NASDAQ TRADE HALT HALT NEWS PENDING AT 04:01 PM
U.S. RESEARCH ROUNDUP- Amazon, Apple, Cigna
Brief: Contineum Therapeutics Reports Positive Topline Phase 1b PET Data for PIPE-791
Brief: Contineum Therapeutics Cash Runway Projected Through 2027 - SEC Filing
Brief: Contineum Therapeutics Provides Update On Phase 1B Positron Emission Tomography Trial Of Pipe-791
Brief: Contineum Therapeutics Inc Files For Mixed Shelf Of Up To $300 Million
Brief: Contineum Therapeutics Appoints Timothy Watkins As Chief Medical Officer And Head Of Development
Brief: Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones
Brief: Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791
Brief: Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
Brief: Rapt Therapeutics Names Lori Lyons-Williams Chair Of The Board
Brief: Contineum Therapeutics Initiates Patient Dosing In Phase 1B Positron Emission Tomography (Pet) Trial Of Pipe-791
Brief: Contineum Therapeutics Expands Clinical Development Of PIPE-791
U.S. RESEARCH ROUNDUP-BXP, Hubspot, Qualcomm
U.S. RESEARCH ROUNDUP-Galapagos, Marsh & Mclennan, Travelers
U.S. RESEARCH ROUNDUP-Agenus, Guardant Health, Zoetis
U.S. RESEARCH ROUNDUP- Domino's Pizza, HCA Healthcare, HCA Healthcare
Brief: Suvretta Capital Management Llc Reports 9.3% Passive Stake In Contineum Therapeutics As Of April 5 - SEC Filing